Merging with Pfizer’s Upjohn off-patent unit will dramatically remould Mylan’s business model, according to the leadership team of the combined company that is expected to be operational from mid-2020.
The deal – announced on 29 July – will see the firms combined in an all-stock transaction under a ‘reverse...




